In a multicenter, randomized, double-blind, placebo-controlled ISLAND investigation (Irbesartan and Lipoic Acid in Endothelial Dysfunction), it was also found that in the group of patients receiving ALA (n = 15) per os at a dose of 300 mg/day there was a significant 15% decrease in IL-6 levels within 4 weeks [15]. This evidence concerns the gene IL6 and endothelial dysfunction.